Welcome to our dedicated page for HEMOGENYX PHARMACEUTICALS news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on HEMOGENYX PHARMACEUTICALS stock.
Hemogenyx Pharmaceuticals plc (LSE:HEMO) is a biopharmaceutical group focused on developing new therapies and treatments for blood diseases. The company's Chimeric Bait Receptor platform shows promise in treating cancers like Non-Hodgkin Lymphoma and solid tumors. Hemogenyx Pharmaceuticals utilizes Artificial Intelligence for protein structure simulations and mRNA synthesis to expedite R&D efforts. With recent FDA consents for Phase I trials of HEMO-CAR-T for AML, the company is advancing towards potentially life-saving treatments.
Hemogenyx Pharmaceuticals announces that Andrew Wright, the Financial Controller and Company Secretary, purchased 1,284,889 ordinary shares at a price of 1.44p each. Post-transaction, Wright holds a total of 4,000,000 shares, representing approximately 0.41% of the company's issued capital. This acquisition signals confidence in the company's future performance, with the transaction value totaling £18,502.40. The purchase occurred on May 27, 2022, on the London Stock Exchange.
Hemogenyx Pharmaceuticals plc has announced its participation in the Immuno-Oncology Summit Europe 2022, taking place from May 23-25, 2022, where Dr. Vladislav Sandler will present on anti-FLT3 CAR-T and bispecific antibody therapies for treating acute myeloid leukemia. This presentation aims to showcase the company’s product candidates, including CDX bispecific antibody and HEMO-CAR-T, highlighting their potential benefits for patients. The participation emphasizes the company's position in the biopharmaceutical sector and aims to enhance visibility among industry leaders.
Hemogenyx Pharmaceuticals has announced that the FDA has deferred its pre-Investigational New Drug meeting for its lead product candidate, HEMO-CAR-T, until May 2022. This change is due to the FDA prioritizing COVID-19 related work, but the company emphasizes that this will not delay HEMO-CAR-T's development or its IND filing. Additionally, progress continues positively on the CDX bispecific antibody for acute myeloid leukaemia and the CBR platform technology for viral diseases. The CEO reassures that the IND application remains on track despite the changes.
Hemogenyx Pharmaceuticals has formed a partnership with Selexis SA to enhance the development of its CDX bispecific antibody targeting acute myeloid leukemia (AML). This collaboration allows Hemogenyx to utilize Selexis' SUREtechnology Platform, streamlining the process of creating high-performance mammalian cell lines for clinical trials. The CDX bispecific antibody is aimed at offering an innovative therapy for AML patients, potentially increasing treatment efficacy and survival rates. The agreement marks a significant step towards advancing Hemogenyx's clinical initiatives.
Hemogenyx Pharmaceuticals announces its participation in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022. CEO Dr. Vladislav Sandler will present the company's progress and product candidates via a virtual platform. The conference aims to enhance the company's visibility and inform investors about its advancements in developing therapies for blood diseases. Hemogenyx focuses on innovative treatments, particularly bone marrow transplantation, to address life-threatening conditions such as leukemia and autoimmune diseases.
Hemogenyx Pharmaceuticals has announced a strategic partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for its HEMO-CAR-T program targeting acute myeloid leukemia (AML). This collaboration aims to accelerate the product development towards phase I clinical trials. The partnership enhances Hemogenyx's ability to produce clinical materials necessary for regulatory submissions. The company anticipates filing an Investigational New Drug (IND) application in 2022. This program is expected to provide a more effective treatment for AML patients.
Hemogenyx Pharmaceuticals has announced progress on its lead product candidate, HEMO-CAR-T, for treating acute myeloid leukemia (AML). The company has requested a pre-Investigational New Drug (PIND) meeting with the FDA, aimed at refining its clinical trial plans and facilitating the IND application process. CEO Dr. Vladislav Sandler emphasized the importance of this step in enhancing the therapy's potential effectiveness, given AML's low survival rates. Successful development could greatly improve treatment outcomes for AML patients. Hemogenyx focuses on innovative therapies for blood diseases.
Hemogenyx Pharmaceuticals has successfully repaid convertible loans totaling $2,110,761 to Orgenesis, Inc., a step originally announced in October 2018. Both subsidiaries, Hemogenyx-Cell and Immugenyx, fulfilled the loan repayment terms. The company is poised for continued progress in developing its product candidates, backed by a substantial cash reserve that supports ongoing product development.
Hemogenyx Pharmaceuticals has secured a lease for a new 10,000 sq. ft. laboratory in New York's Mink Building, aimed at advancing its HEMO-CAR-T cell therapy for acute myeloid leukemia. The facility will feature two clean rooms designed for in-house cell manufacturing. CEO Dr. Vladislav Sandler expressed enthusiasm for the strategic location, citing collaboration opportunities with nearby Columbia University and City College. The move supports the company's anticipated growth and operational flexibility over the coming three years.
FAQ
What is the current stock price of HEMOGENYX PHARMACEUTICALS (HOPHF)?
What is the market cap of HEMOGENYX PHARMACEUTICALS (HOPHF)?
What is Hemogenyx Pharmaceuticals focused on?
What is the significance of the Chimeric Bait Receptor platform?
How does Hemogenyx Pharmaceuticals expedite its R&D efforts?
What recent FDA development has Hemogenyx Pharmaceuticals achieved?
